These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 33267867)

  • 1. Shotgun proteomics coupled to nanoparticle-based biomarker enrichment reveals a novel panel of extracellular matrix proteins as candidate serum protein biomarkers for early-stage breast cancer detection.
    Fredolini C; Pathak KV; Paris L; Chapple KM; Tsantilas KA; Rosenow M; Tegeler TJ; Garcia-Mansfield K; Tamburro D; Zhou W; Russo P; Massarut S; Facchiano F; Belluco C; De Maria R; Garaci E; Liotta L; Petricoin EF; Pirrotte P
    Breast Cancer Res; 2020 Dec; 22(1):135. PubMed ID: 33267867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteomic Profiling of Invasive Ductal Carcinoma (IDC) using Magnetic Beads-based Serum Fractionation and MALDI-TOF MS.
    Yang J; Zhu J; He K; Zhao LY; Liu LY; Song TS; Huang C
    J Clin Lab Anal; 2015 Jul; 29(4):321-7. PubMed ID: 25130542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Candidate early detection protein biomarkers for ER+/PR+ invasive ductal breast carcinoma identified using pre-clinical plasma from the WHI observational study.
    Buas MF; Rho JH; Chai X; Zhang Y; Lampe PD; Li CI
    Breast Cancer Res Treat; 2015 Sep; 153(2):445-54. PubMed ID: 26319120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and validation of new autoantibodies for the diagnosis of DCIS and node negative early-stage breast cancers.
    Lacombe J; Mangé A; Jarlier M; Bascoul-Mollevi C; Rouanet P; Lamy PJ; Maudelonde T; Solassol J
    Int J Cancer; 2013 Mar; 132(5):1105-13. PubMed ID: 22886747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast invasive ductal carcinoma diagnosis with a three-miRNA panel in serum.
    Chen X; Li X; Wang J; Zhao L; Peng X; Zhang C; Liu K; Huang G; Lai Y
    Biomark Med; 2021 Aug; 15(12):951-963. PubMed ID: 34293926
    [No Abstract]   [Full Text] [Related]  

  • 6. Factors predictive of invasive ductal carcinoma in cases preoperatively diagnosed as ductal carcinoma in situ.
    Takada K; Kashiwagi S; Asano Y; Goto W; Morisaki T; Takahashi K; Fujita H; Takashima T; Tomita S; Hirakawa K; Ohira M
    BMC Cancer; 2020 Jun; 20(1):513. PubMed ID: 32493410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Application of serum proteomic mass spectrum analysis in breast cancer].
    Ying MG; Chen Q; Ye YB; Chen HJ; Chen X; Zheng HY; Wu F
    Zhonghua Zhong Liu Za Zhi; 2010 Sep; 32(9):698-702. PubMed ID: 21122387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating Serum Markers for Hormone Receptor-Negative Breast Cancer.
    Schummer M; Thorpe J; Giraldez MD; Bergan L; Tewari M; Urban N
    PLoS One; 2015; 10(11):e0142911. PubMed ID: 26565788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer.
    Ostroff RM; Bigbee WL; Franklin W; Gold L; Mehan M; Miller YE; Pass HI; Rom WN; Siegfried JM; Stewart A; Walker JJ; Weissfeld JL; Williams S; Zichi D; Brody EN
    PLoS One; 2010 Dec; 5(12):e15003. PubMed ID: 21170350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multiparametric serum marker panel as a complementary test to mammography for the diagnosis of node-negative early-stage breast cancer and DCIS in young women.
    Lacombe J; Mangé A; Bougnoux AC; Prassas I; Solassol J
    Cancer Epidemiol Biomarkers Prev; 2014 Sep; 23(9):1834-42. PubMed ID: 24957886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a Fit-For-Purpose Multi-Marker Panel for Early Diagnosis of Pancreatic Ductal Adenocarcinoma.
    Kim H; Huh S; Park J; Han Y; Ahn KG; Noh Y; Lee SJ; Chu H; Kim SS; Jung HS; Yun WG; Cho YJ; Kwon W; Jang JY; Kang UB
    Mol Cell Proteomics; 2024 Sep; 23(9):100824. PubMed ID: 39097268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteomic investigation on bio-corona of Au, Ag and Fe nanoparticles for the discovery of triple negative breast cancer serum protein biomarkers.
    Del Pilar Chantada-Vázquez M; López AC; Vence MG; Vázquez-Estévez S; Acea-Nebril B; Calatayud DG; Jardiel T; Bravo SB; Núñez C
    J Proteomics; 2020 Feb; 212():103581. PubMed ID: 31731051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer.
    Berg WA; Gutierrez L; NessAiver MS; Carter WB; Bhargavan M; Lewis RS; Ioffe OB
    Radiology; 2004 Dec; 233(3):830-49. PubMed ID: 15486214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CE-Magnetic Resonance Mammography for the evaluation of the contralateral breast in patients with diagnosed breast cancer.
    Pediconi F; Venditti F; Padula S; Roselli A; Moriconi E; Giacomelli L; Catalano C; Passariello R
    Radiol Med; 2005; 110(1-2):61-8. PubMed ID: 16163140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A proteomic signature of ovarian cancer tumor fluid identified by highthroughput and verified by targeted proteomics.
    Poersch A; Grassi ML; Carvalho VP; Lanfredi GP; Palma CS; Greene LJ; de Sousa CB; Carrara HHA; Candido Dos Reis FJ; Faça VM
    J Proteomics; 2016 Aug; 145():226-236. PubMed ID: 27222041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of vitronectin as a novel serum marker for early breast cancer detection using a new proteomic approach.
    Kadowaki M; Sangai T; Nagashima T; Sakakibara M; Yoshitomi H; Takano S; Sogawa K; Umemura H; Fushimi K; Nakatani Y; Nomura F; Miyazaki M
    J Cancer Res Clin Oncol; 2011 Jul; 137(7):1105-15. PubMed ID: 21253761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An integrated cell line-based discovery strategy identified follistatin and kallikrein 6 as serum biomarker candidates of breast carcinoma.
    Mangé A; Dimitrakopoulos L; Soosaipillai A; Coopman P; Diamandis EP; Solassol J
    J Proteomics; 2016 Jun; 142():114-21. PubMed ID: 27168011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological predictors of postoperative upstaging to invasive ductal carcinoma (IDC) in patients preoperatively diagnosed with ductal carcinoma in situ (DCIS): a multi-institutional retrospective cohort study.
    Tanaka K; Masuda N; Hayashi N; Sagara Y; Hara F; Kadoya T; Matsui A; Miyazaki C; Shien T; Tokunaga E; Hayashi T; Niikura N; Maeda S; Komoike Y; Bando H; Kanbayashi C; Iwata H
    Breast Cancer; 2021 Jul; 28(4):896-903. PubMed ID: 33599914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteomics-Based Identification of Dysregulated Proteins and Biomarker Discovery in Invasive Ductal Carcinoma, the Most Common Breast Cancer Subtype.
    Neagu AN; Whitham D; Seymour L; Haaker N; Pelkey I; Darie CC
    Proteomes; 2023 Apr; 11(2):. PubMed ID: 37092454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteomic Analysis of Urine to Identify Breast Cancer Biomarker Candidates Using a Label-Free LC-MS/MS Approach.
    Beretov J; Wasinger VC; Millar EK; Schwartz P; Graham PH; Li Y
    PLoS One; 2015; 10(11):e0141876. PubMed ID: 26544852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.